Guidepoint Qsight’s new analytics tool examines treatment pairings, repeat visits, and cross-purchasing trends across medical aesthetics.
Medical aesthetics data and intelligence provider Guidepoint Qsight announced the launch of its Cross-Purchasing Dashboard, an analytical tool designed to help practices and manufacturers better understand patient consumption patterns. Based on Guidepoint Qsight’s transaction data, the dashboard provides visualizations of cross-purchasing metrics, including basket analysis and repeat purchasing trends, measured across products, categories, age groups, practice types, geographic regions, and time periods.
“Qsight’s Cross-Purchasing Dashboard provides the aesthetics industry with a level of insight not previously available. Historically, much of the understanding around patient behavior and treatment pairing was anecdotal or intuition-based, largely due to lack of good data and information at scale. Our new dashboard connects these dots with real data,” says Erik Haines, managing director of Guidepoint Qsight, in a release. “For example, at the start of 2018, 20% of neurotoxin procedures in medical aesthetics practices were performed alongside a dermal filler treatment; by early 2026, this share had declined to 13%, indicating a weakening association between two categories traditionally adjacent to each other.”
Examples of analyses available through the dashboard include:
- Percentage of neurotoxin visits that included a dermal filler procedure, including brand-level comparisons
- Percentage of mechanical microneedling visits that included a professional-grade skincare purchase
- Percentage of neurotoxin visits followed by a repeat procedure within a month, year, or same visit
- Measurement of cross-purchasing rates across treatments and product categories
- Analysis of cross-purchasing trends over time
The dashboard also analyzes trends in which treatments and brands patients purchase and how those purchases are combined over time.
“The dashboard has allowed us to see, for example, that neurotoxins have been a gateway treatment into aesthetics. Based on transaction data from the past two years, neurotoxin procedures are responsible for about a third of all first-time non-surgical aesthetic patient visits,” says Erika Sheyn, senior vice president of aesthetics at Guidepoint Qsight, in a release. “As the industry continues to grow, Qsight’s Cross-Purchasing Dashboard will provide manufacturers valuable guidance to better and more quickly understand patients’ evolving relationship with medical aesthetics, while helping marketers to more accurately target their audiences.”
